NEW YORK – Rapid molecular testing for sexually transmitted infections has been on the horizon for two decades, and with US Food and Drug Administration clearance earlier this month of Binx Health's Binx io instrument and assay for chlamydia and gonorrhea, a new market opportunity may now have opened for many other tests and systems currently in development.
The clearance marks a milestone for one group in particular — Charlotte Gaydos and a point-of-care STI diagnostics development center she helped to establish at Johns Hopkins University.